CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable ...
NEW YORK, May 9, 2025 /PRNewswire/ -- American Liver Foundation (ALF) is excited to announce today the 2025 winners of their Liver Health Poster Competition. This competition showcases posters and a ...
Vanoglipel (DA-1241) is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes (T2D). Agonism ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results